Magnetic Resonance-Guided Laser Ablation for the Treatment of Recurrent Dural-Based Lesions: A Series of Five Cases

被引:30
作者
Ivan, Michael E. [1 ,2 ]
Diaz, Roberto Jose [1 ,2 ]
Berger, Michael H. [2 ]
Basil, Gregory W. [1 ,2 ]
Osiason, David A. [2 ]
Plate, Thomas [2 ]
Wallo, Amanda [3 ]
Komotar, Ricardo J. [1 ,2 ]
机构
[1] Sylvester Comprehens Canc Ctr, Dept Neurol Surg, Miami, FL 33136 USA
[2] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami, FL 33136 USA
[3] Visualase Inc, Miami, FL USA
关键词
Brain tumors; Dural-based lesions; Laser-induced thermotherapy; Meningiomas Minimally invasive neurosurgery; Magnetic resonance-guided laser-induced thermotherapy; INTERSTITIAL THERMAL THERAPY; PHASE-II TRIAL; BRAIN-TUMORS; NEUROBLATE SYSTEM; MENINGIOMAS; GLIOBLASTOMAS; THERMOTHERAPY; NEOPLASMS; RADIATION; EPILEPSY;
D O I
10.1016/j.wneu.2016.10.037
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
BACKGROUND AND OBJECTIVE: Magnetic resonanceguided laser-induced thermotherapy (MR-LITT) is a minimally invasive technique that shows promise in neurooncology because of its superiority in delivering precise minimally invasive thermal energy with minimal collateral damage. In this analysis, we investigate initial data on the effect of MR-LITT on dural-based lesions. METHODS: Five patients were identified with duralbased lesions (4 meningiomas, 1 solitary fibrous tumor) with clear evidence of radiologic progression. In all 5 cases, the tumors were localized to the lateral convexity or paramedian locations in the supratentorial space. All patients received MR-LITT and then a follow-up magnetic resonance imaging scan at 24 hours after treatment, at 1 month, and at each subsequent follow-up visit. Local control of the ablated tumor was evaluated with radiographic follow-up and symptomatic progression-free survival was recorded. RESULTS: Five LITT treatments were performed on 5 patients with an average age of 65.2 years. The average tumor volume was 29.7 cm(3) and ablation dosage was 12.4 W. On average, 80% of the pretreatment lesion volume was ablated. The mean follow-up time was 59.3 weeks. In total, 2 patients (1 with an anaplastic meningioma and 1 with a solitary fibrous tumor) had radiographic evidence of disease progression. In the observed time of the 3 patients with no progression, there was a 52% reduction in tumor volume. There were no major perioperative complications. CONCLUSIONS: MR-LITT is a promising technology for dural-based lesion treatment. This initial study demonstrates that MR-LITT is safe and offers several advantages over open surgical treatment. Randomized studies are needed to evaluate its role as a treatment adjunct.
引用
收藏
页码:162 / 170
页数:9
相关论文
共 24 条
  • [21] MR-guided laser irradiation of recurrent glioblastomas
    Schwarzmaier, HJ
    Eickmeyer, F
    von Tempelhoff, W
    Fiedler, VU
    Niehoff, H
    Ulrich, SD
    Ulrich, F
    [J]. JOURNAL OF MAGNETIC RESONANCE IMAGING, 2005, 22 (06) : 799 - 803
  • [22] Results of the NeuroBlate System first-in-humans Phase I clinical trial for recurrent glioblastoma Clinical article
    Sloan, Andrew E.
    Ahluwalia, Manmeet S.
    Valerio-Pascua, Jose
    Manjila, Sunil
    Torchia, Mark G.
    Jones, Stephen E.
    Sunshine, Jeffrey L.
    Phillips, Michael
    Griswold, Mark A.
    Clampitt, Mark
    Brewer, Cathy
    Jochum, Jennifer
    McGraw, Mary V.
    Diorio, Dawn
    Ditz, Gail
    Barnett, Gene H.
    [J]. JOURNAL OF NEUROSURGERY, 2013, 118 (06) : 1202 - 1219
  • [23] Laser ablation therapy: An alternative treatment for medically resistant mesial temporal lobe epilepsy after age 50
    Waseem, Hena
    Osborn, Katie E.
    Schoenberg, Mike R.
    Kelley, Valerie
    Bozorg, Ali
    Cabello, Daniel
    Benbadis, Selim R.
    Vale, Fernando L.
    [J]. EPILEPSY & BEHAVIOR, 2015, 51 : 152 - 157
  • [24] Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08)
    Wen, Patrick Y.
    Yung, W. K. Alfred
    Lamborn, Kathleen R.
    Norden, Andrew D.
    Cloughesy, Timothy F.
    Abrey, Lauren E.
    Fine, Howard A.
    Chang, Susan M.
    Robins, H. Ian
    Fink, Karen
    DeAngelis, Lisa M.
    Mehta, Minesh
    Di Tomaso, Emmanuelle
    Drappatz, Jan
    Kesari, Santosh
    Ligon, Keith L.
    Aldape, Ken
    Jain, Rakesh K.
    Stiles, Charles D.
    Egorin, Merrill J.
    Prados, Michael D.
    [J]. NEURO-ONCOLOGY, 2009, 11 (06) : 853 - 860